Premium
Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
Author(s) -
Pacini G.,
Mari A.,
Fouqueray P.,
Bolze S.,
Roden M.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12452
Subject(s) - medicine , insulin , endocrinology , type 2 diabetes , diabetes mellitus , metformin , area under the curve , placebo , c peptide , alternative medicine , pathology
Aims To assess the glucose‐stimulated insulin secretion effect of imeglimin in patients with type 2 diabetes. Methods We conducted a double‐blind, randomized, placebo‐controlled study in 33 patients with type 2 diabetes [glycated haemoglobin 6.8 ± 0.1% (51 mmol/mol)], who were drug‐naïve or withdrawn from their previous metformin monotherapy for 2 weeks and received imeglimin 1500 mg twice daily or placebo for 1 week. Glucose‐stimulated insulin secretion was assessed using a hyperglycaemic clamp. The primary endpoint was insulin secretion as defined by total insulin response [incremental area under the curve ( iAUC ) 0–45 min ] and insulin secretion rate ( ISR ) calculated from C‐peptide deconvolution. β‐cell glucose sensitivity at steady state (second phase: 25–45 min), hepatic insulin extraction and insulin clearance were also calculated. Results Imeglimin treatment for 7 days raised the insulin secretory response to glucose by +112% ( iAUC 0‐45 , p = 0.035), first‐phase ISR by +110% (p = 0.034) and second‐phase ISR by +29% (p = 0.031). Imeglimin improved β‐cell glucose sensitivity by +36% (p = 0.034) and tended to decrease hepatic insulin extraction (−13%; p = 0.056). Imeglimin did not affect glucagon secretion. Conclusions In patients with type 2 diabetes, imeglimin improves β‐cell function, which may contribute to the glucose‐lowering effect observed with imeglimin in clinical trials.